<DOC>
	<DOCNO>NCT00005848</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness R115777 treat patient progressive , metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>R115777 Treating Patients With Progressive , Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether R115777 antitumor activity patient progressive , metastatic , hormone refractory prostate cancer . II . Determine safety pharmacokinetics regimen patient population . OUTLINE : Patients receive oral R115777 every 12 hour day 1-21 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 10-16 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate evidence bone , pelvic , lymph node , liver , lung metastasis Radiologic evidence hydronephrosis alone constitute evidence metastatic disease Patients bone metastasis ( i.e. , measurable soft tissue disease ) must PSA level least 5 ng/mL Prior bilateral orchiectomy prior primary hormonal therapy ( e.g. , estrogen therapy , LHRH agonist without flutamide bicalutamide ) evidence treatment failure Patients without prior orchiectomy must continue LHRH agonist therapy At least 4 week since prior flutamide ( least 6 week since prior bicalutamide nilutamide ) continue evidence progressive disease ( i.e. , increase PSA ) Must evidence progressive disease , define one follow completion primary hormonal therapy ( must include either orchiectomy LHRH agonist therapy ) : Rising PSA , define least 50 % increase nadir value achieve prior therapy Increase confirm second measurement obtain minimum 1 week follow index measurement , confirm third measurement second value less first increase One new bone metastasis radionuclide bone scan xray film New enlarge soft tissue metastasis Disease relate symptom pain require Ineligible elevated serum acid phosphatase PSA level evidence disease No history brain metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No active angina pectoris No New York Heart Association class IIIV heart disease No myocardial infarction within past 6 month Other : Fertile patient must use effective contraception 3 month study No malignancy within past 3 year No serious concurrent medical illness active infection would preclude study chemotherapy No allergy sensitivity imidazole antifungal medication ( e.g. , fluconazole , ketoconazole , miconazole , itraconazole , clotrimazole ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic filgrastim ( GCSF ) , sargramostim ( GMCSF ) , thrombopoietin Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy ( e.g. , antiandrogens megestrol acetate ) except adrenal replacement dose corticosteroid Radiotherapy : No prior strontium chloride Sr 89 , samarium Sm 153 lexidronam pentasodium , radioisotope therapy At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : At least 1 week since prior concurrent cholesterol lower medication ( e.g. , lovastatin , simvastatin ) At least 1 week since prior concurrent proton pump inhibitor ( e.g. , omeprazole , lansoprazole ) Concurrent H2 receptor antagonist antacids allow least 2 hour follow administration R115777 No concurrent bisphosphonates ( e.g. , pamidronate , zoledronate ) No concurrent imidazole antifungal medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>